Gardasil 9 Human Papillomavirus Vaccine (HPV vaccine) Recombinant, 20 mcg - 60 mcg (10-Pack) **Requires Refrigeration (RX)

Gardasil 9 is a Human Papillomavirus (HPV) vaccine used to protect against cancers caused by HPV, including cervical, anal, and throat cancers, as well as genital warts. It offers protection against nine HPV types, significantly reducing the risk of infection. Administered through a series of injections, this vaccine plays a crucial role in preventive healthcare. It is effective in promoting immune protection and enhancing overall public health by reducing HPV-related disease prevalence.

Gardasil 9 is a leading vaccine designed to provide robust protection against certain strains of Human Papillomavirus (HPV). Manufactured by Merck, this recombinant vaccine targets nine HPV types—6, 11, 16, 18, 31, 33, 45, 52, and 58—responsible for the majority of HPV-related cancers and diseases. With its advanced formulation, Gardasil 9 empowers individuals to safeguard their health and reduce the risk of developing HPV-related cervical, vulvar, vaginal, anal, and oropharyngeal cancers, as well as genital warts.

Details and Features:

• Dosage Strengths: Offers antigen levels ranging from 20 mcg to 60 mcg, tailored to confer optimal immunity.
• Comprehensive Protection: Covers nine HPV types responsible for approximately 90% of cervical cancer cases.
• Target Audience: Approved for use in both males and females, typically starting from ages 9 to 45.
• Formulation: Recombinant vaccine, meaning it uses a safe, non-infectious virus-like particle (VLP) to elicit an immune response.
• Administration: Administered via intramuscular injection, typically in a series of two or three doses depending on the age and health status of the recipient.

Mechanism of Action:

Gardasil 9 works by introducing non-infectious VLPs resembling the HPV virus to the body. This prompts the immune system to produce antibodies, equipping the body to recognize and neutralize the actual virus if exposed in the future. The vaccine does not contain live virus, ensuring safety while effectively stimulating a protective immune response.

Directions for Use:

1. Vaccination Schedule:

   • Ages 9-14: Two doses, with a second dose given 6-12 months after the first.
   • Ages 15-45 and Immunocompromised Individuals: Three doses, with the second and third doses given two and six months after the first, respectively.

2. Route of Administration: Administered intramuscularly, typically in the upper arm or thigh.

Warnings:

• Allergic Reactions: Immediate medical attention is required for severe allergic reactions, such as difficulty breathing, wheezing, hives, or swelling.
• Pregnancy and Breastfeeding: Not recommended for pregnant women; if pregnancy is discovered post-vaccination, notify your healthcare provider. Consult a doctor before receiving the vaccine while breastfeeding.
• Syncope (Fainting): Patients should be observed for at least 15 minutes post-vaccination to manage any immediate adverse reactions, including fainting.

Side Effects:

Common side effects may include:

• Injection-site reactions: Pain, swelling, or redness
• Headache
• Fever
• Nausea
• Dizziness
• Fatigue

Most side effects are mild and resolve on their own. Contact your healthcare provider if you experience persistent or severe symptoms.

Gardasil 9 is a pivotal tool in the prevention of HPV-related diseases. Consult your healthcare provider to learn if Gardasil 9 is appropriate for you or your loved ones, and take proactive steps to protect against HPV.